Medical news of Remedium.ru portal is the most update information on pharmaceutical and medical equipment market

Journals

REMEDIUM

The periodical about the pharmaceutical and medical equipment markets

ROSSIYSKIE APTEKI

(Russian pharmacies) - specialized periodical edition for pgarmacy professionals

MEDITSINSKY SOVET

Medical Council - Scientific Journal for Physicians


Home / News

07.03.2017

Biocad gets first-ever biosimilar of interferon beta-1a approved in Russia

The Russian Ministry of Health (MoH) has awarded domestic biotech firm Biocad marketing authorization for its interferon beta-1a biosimilar, a knockoff of Merck KGaA's (MRK: DE) Biogen’s Rebif that is a key component in treatment of relapsing-remitting multiple sclerosis (RRMS) and included in all international recommendations and protocols.

Biocad says it started the development program for interferon beta-1a biosimilar in 2012 and it took almost five years to run all the development phases, including pre-clinical/clinical studies and registration. The new biosimilar will be available for Russian patients already in 2017.

At present, Biocad says its interferon beta-1a biosimilar is the only registered biosimilar of Rebif in Russia and worldwide, which was developed in accordance with European Medicine Agency guidelines. It showed no statistically-meaningful difference in pharmacokinetics and pharmacodynamics parameters during Phase I study and proved safety and efficacy equivalence to reference medicine in phase III study.

Included in the federal list of essential drugs and special reimbursement program for medicines used in rare debilitating diseases, interferon beta-1a is one of the most demanded therapeutic proteins the Russian government reimburses.

Roman Ivanov, R&D vice-president of Biocad, said: “Interferon beta-1a biosimilar is the third authorized Biocad’s medicine for treatment of RRMS, which makes our biotechnological company the only manufacturer of both active pharmaceutical ingredients and drug products for all first generation disease-modifying therapies (DMTs). Moreover, five other drugs for use in MS, including 2 novel molecules, are in different development phases, supplementing the Biocad’s autoimmune diseases pipeline”



Source:  www.thepharmaletter.com

Remedium group

REMEDIUM

publishing house

CLIFAR

programmer of electronic software products

R-PRESS

advertisement agency

REPRENT

rent-a-rep company